SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less.....
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: lexi2004 who wrote (57666)2/25/2007 5:08:28 PM
From: Findit  Read Replies (1) of 59879
 
DORB - From today's Miami Herald - CEO Schaber remained upbeat. He said Cell Therapeutics is not alone in bidding on DOR and plans to listen to all offers. ``There's other interest out there, and we need to maximize shareholder value.''

In a presentation for industrial conferences, DOR estimates orBec could have a $200 million annual market worldwide and, because it is serving a severe, unmet need, the FDA is likely to declare it an orphan drug, extending its exclusivity. The firm says that it can continue to develop and market orBec on its own -- assuming it gets approval.

''This is a very interesting time,'' says Schaber. ``There's always a risk.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News